

Aurealis Pharma to Present at Swiss Biotech Day on May 4th 2017

Basel Switzerland – April 24th 2017

Aurealis Pharma, a private biopharmaceutical company developing novel lactic acid bacteria based multitherapy biologics for patients with chronic inflammation and cancer, today announced that CEO Juha Yrjänheikki will attend and present at The Swiss Biotech Day (SBD), the leading biotechnology conference in Switzerland on May 4th 2017 held in Congress Center Basel.

“We are looking forward to attend and present our progress in the emerging companies session and in the one-on-one partnering meetings. The company is at very exciting stage with lead product AUP-16 for diabetic foot ulcer entering clinical stage in 2018 and AUP-5550 for cancer generating non-clinical proof-of-concept data” Said Dr. Yrjänheikki.

The Swiss Biotech Day has long become the standard annual get-together of the Swiss bio-pharmaceutical industry. And Basel, as one of the most vivid cities in terms of biotechnological and pharmaceutical research, development and production, proved to be the ideal location. Now in its 19th year, the SBD is not just the place to be for members of the Swiss Biotech Association, who traditionally meet there for the association’s Annual General Assembly. As always, the event targets entrepreneurs, investors, researchers, analysts, political decision makers and industry stakeholders.

Aurealis Pharma is a Basel Switzerland and Kuopio Finland based privately-held biopharmaceutical company focusing on developing broadly applicable proprietary technology to effectively, safely and economically modulate and re-educate the distorted host immune microenvironment to proper state in chronic inflammation and cancer. Company’s technology is based on safe food-grade lactic acid bacteria delivering multiple human therapeutic proteins in target tissue to address the unmet medical need in chronic wounds and cancer.

For more information:
Juha Yrjänheikki, CEO
Aurealis Pharma
Tel: +358 45 8433550



AUREALIS PHARMA
Hochbergerstrasse 60C
CH-4058 Basel
Switzerland
www.aurealispharma.com

Microkatu 1
FI-70210 Kuopio
Finland

Email: [juha\(at\)aurealispharma.com](mailto:juha(at)aurealispharma.com)

www.aurealispharma.com



AUREALIS PHARMA
Hochbergerstrasse 60C
CH-4058 Basel
Switzerland
www.aurealispharma.com

Microkatu 1
FI-70210 Kuopio
Finland